Perhaps it reflects a greater focus on core competencies or an increased emphasis on specialty indications, particularly within oncology; or maybe it is just a sign of smarter portfolio management. Opinions vary on the motivations but not about the reality that large pharma companies are doing a lot of divestment and licensing deals.
In 2018, the 20 largest biopharmas completed 31 such deals according to Pharma Intelligence’s Strategic Transactions database – and that...